Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1534120 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $19.01Day −2.61%Mkt cap $999M1Y +190.7%Off 52W high −21.7%Vol (1Y) 92.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,101 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest24.1% of sh out |
| Days to cover10.7d |
| 13F net flow (QoQ)+12.24% |
| Top-10 13F concentration48.3% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$59,000 |
| Earnings (TTM)-$84.7M |
| ROE−72.4% |
| Net margin−132642.4% |
| Sales growth 3Y−85.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+4.7% |
| 1Y+190.7% |
| 3Y−60.4% |
| Since incept. (ann.)−71.2% |
Price return through 2026-07-29 · series begins 2021-08-27. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)92.0% |
| Ann. volatility (3Y)243.2% |
| Sharpe (1Y)1.61 |
| Sharpe (3Y)0.47 |
| Max drawdown (1Y)−44.3% |
| Max drawdown (3Y)−93.3% |
| Beta (3Y vs SPY)0.85 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 2.9M | $43M | — | +1207.1% |
| T. Rowe Price Investment Management, Inc. | 2.2M | $32M | — | new |
| Caligan Partners LP | 1.6M | $24M | — | +85.5% |
| BVF INC/IL | 1.6M | $24M | — | +20.5% |
| Avoro Capital Advisors LLC | 1.4M | $21M | — | new |
| Affinity Asset Advisors, LLC | 1.3M | $20M | — | +27.6% |
| Nantahala Capital Management, LLC | 1.2M | $18M | — | +0.0% |
| UBS Group AG | 1.1M | $17M | — | +139.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding suppressed: the summed institutional 13F holdings (31,599,256) exceed the cover-page shares-outstanding count for this quarter (22,788,452, as of 2026-03-18) by more than securities-lending double counting can explain (FINRA short interest 5,733,586 shares at 2026-04-30), so the share count is stale or wrong (common for annual 20-F foreign private issuers after a share issuance) and a percentage would be fabricated. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.98 | — | — | — |
| 2025-09-30 | 2025-11-06 | −$2.19 | — | $0 | −100.0% |
| 2025-06-30 | 2025-08-07 | −$1.92 | — | — | — |
| 2025-03-31 | 2025-05-12 | −$1.25 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Product 100%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
